CLNN
Clene Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.85
−3.63%Aug 14, 2026, 14:22 UTC
Clene Inc. reported a quarterly loss of $0.6 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.37, but beating revenue estimates.
Source:Aug 12, 2026, 10:02 UTC
Clene announced it will submit a new drug application (NDA) for CNM-Au8 as an ALS treatment in early Q4 2026, following FDA meetings.
Source: